241 related articles for article (PubMed ID: 29084032)
1. DosOpt: A Tool for Personalized Bayesian Dose Adjustment of Vancomycin in Neonates.
Tasa T; Metsvaht T; Kalamees R; Vilo J; Lutsar I
Ther Drug Monit; 2017 Dec; 39(6):604-613. PubMed ID: 29084032
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.
Mehrotra N; Tang L; Phelps SJ; Meibohm B
Pharmacotherapy; 2012 May; 32(5):408-19. PubMed ID: 22488303
[TBL] [Abstract][Full Text] [Related]
3. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
Padari H; Oselin K; Tasa T; Metsvaht T; Lõivukene K; Lutsar I
BMC Pediatr; 2016 Dec; 16(1):206. PubMed ID: 27931193
[TBL] [Abstract][Full Text] [Related]
4. Vancomycin population pharmacokinetics in neonates.
de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle.
Allegaert K; Flint R; Smits A
Expert Opin Drug Metab Toxicol; 2019 Sep; 15(9):735-749. PubMed ID: 31402708
[No Abstract] [Full Text] [Related]
6. Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting.
Broeker A; Nardecchia M; Klinker KP; Derendorf H; Day RO; Marriott DJ; Carland JE; Stocker SL; Wicha SG
Clin Microbiol Infect; 2019 Oct; 25(10):1286.e1-1286.e7. PubMed ID: 30872102
[TBL] [Abstract][Full Text] [Related]
7. Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates.
Kato H; Hagihara M; Nishiyama N; Koizumi Y; Mikamo H; Matsuura K; Yamagishi Y
J Infect Chemother; 2017 Mar; 23(3):154-160. PubMed ID: 28017667
[TBL] [Abstract][Full Text] [Related]
8. The Effectiveness of a Vancomycin Dosing Guideline in the Neonatal Intensive Care Unit for Achieving Goal Therapeutic Trough Concentrations.
Reilly AM; Ding MX; Rower JE; Kiser TH
J Clin Pharmacol; 2019 Jul; 59(7):997-1005. PubMed ID: 30776089
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin in Pediatric Patients with Solid or Hematological Malignant Disease: Predictive Performance of a Population Pharmacokinetic Model and New Optimized Dosing Regimens.
Marsot A; Gallais F; Galambrun C; Coze C; Blin O; Andre N; Guilhaumou R
Paediatr Drugs; 2018 Aug; 20(4):375-381. PubMed ID: 29736878
[TBL] [Abstract][Full Text] [Related]
10. Optimisation of vancomycin exposure in neonates based on the best level of evidence.
Dao K; Guidi M; André P; Giannoni E; Basterrechea S; Zhao W; Fuchs A; Pfister M; Buclin T; Csajka C
Pharmacol Res; 2020 Apr; 154():104278. PubMed ID: 31108184
[TBL] [Abstract][Full Text] [Related]
11. Pilot Study of a Bayesian Approach To Estimate Vancomycin Exposure in Obese Patients with Limited Pharmacokinetic Sampling.
Carreno JJ; Lomaestro B; Tietjan J; Lodise TP
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28289024
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support.
Cies JJ; Moore WS; Nichols K; Knoderer CA; Carella DM; Chopra A
Pediatr Crit Care Med; 2017 Oct; 18(10):977-985. PubMed ID: 28650363
[TBL] [Abstract][Full Text] [Related]
13. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing.
Tang Z; Guan J; Li J; Yu Y; Qian M; Cao J; Shuai W; Jiao Z
Int J Antimicrob Agents; 2021 Mar; 57(3):106300. PubMed ID: 33567334
[TBL] [Abstract][Full Text] [Related]
14. Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations.
Kim J; Walker SA; Iaboni DC; Walker SE; Elligsen M; Dunn MS; Allen VG; Simor A
Antimicrob Agents Chemother; 2014 May; 58(5):2830-40. PubMed ID: 24614381
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.
Nunn MO; Corallo CE; Aubron C; Poole S; Dooley MJ; Cheng AC
Ann Pharmacother; 2011 Jun; 45(6):757-63. PubMed ID: 21652786
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.
Lo YL; van Hasselt JG; Heng SC; Lim CT; Lee TC; Charles BG
Antimicrob Agents Chemother; 2010 Jun; 54(6):2626-32. PubMed ID: 20385872
[TBL] [Abstract][Full Text] [Related]
17. Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.
Morrill HJ; Caffrey AR; Noh E; LaPlante KL
Pharmacotherapy; 2015 Sep; 35(9):869-75. PubMed ID: 26343549
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a population pharmacokinetics model of vancomycin in 94 infants with septicemia and its application in individualized therapy.
Li Z; Li H; Wang C; Jiao Z; Xu F; Sun H
BMC Pharmacol Toxicol; 2021 May; 22(1):26. PubMed ID: 33947475
[TBL] [Abstract][Full Text] [Related]
19. Vancomycin dosing in children and young adults: back to the drawing board.
Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Ampicillin in Neonates with Hypoxemic-Ischemic Encephalopathy in the Setting of Controlled Hypothermia.
Cies JJ; Fugarolas KN; Moore WS; Mason RW; Menkiti OR
Pharmacotherapy; 2017 Apr; 37(4):456-463. PubMed ID: 28226400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
